Annotation Detail

Information
Associated Genes
ROS1
Associated Variants
ROS1 CD74-ROS1 L2026M
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays. After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested. Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1253
Gene URL
https://civic.genome.wustl.edu/links/genes/4941
Variant URL
https://civic.genome.wustl.edu/links/variants/516
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Lorlatinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
25733882
Drugs
Drug NameSensitivitySupported
LorlatinibSensitivitytrue